SZStefano Zanigni

Stefano Zanigni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefano Zanigni has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial

    by Lotte Kjærsgaard, Jonas Wiedemann, Wolfgang Singer, Atsushi Takeda, Anna-Karin Berger, Mimi Folden Flensburg, Lene Hansen, Pekka Kallunki, Kristiina Kompus, Krishan Nighah, et al.


  • Open Access

    Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment

    by Tobias Sydendal Grand, Shijie Ren, Praveen Thokala, Stefano Zanigni, Daniel Oudin Åström, Aroussi Bidani, Günter Höglinger, Werner Poewe, Florian Krismer, Stephane Regnier

    Background and Objectives Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Little is known about available health-economic parameters for multiple system atrophy, and it remains unclear if the current available data are sufficient to construct an early health technology assessment. This assessment considered (i) if data gaps can be minimised or cost-effectiveness modelling can be facilitated by conducting literature searches for disease analogues, (ii) if an early health technology assessment is feasible with the currently available data, and (iii) the potential for developing user-friendly model interfaces in rare diseases. Methods Literature searches were conducted for economic evaluations and health-economic parameters (including costs, utilities, natural history of disease) for multiple system atrophy. The searches for disease analogues focussed on economic evaluations and showed a widespread use of functional or disability scales to inform model structures; we therefore used the unified multiple system atrophy rating scale part IV (global disability scale) to inform the model structure. Natural history of disease data were used to inform utilities and transition probabilities. Analyses of a hypothetical intervention were conducted from the perspective of the United Kingdom National Health Service with a cost-effectiveness threshold of £30,000 per quality-adjusted life year. The cost-effectiveness analysis was presented using a user-friendly interface in R Shiny, which provides stakeholders with an opportunity to explore results. Results Cost-effectiveness analyses were not identified for multiple system atrophy; however, two cost-of-illness, 20 quality-of-life, and nine natural history of disease studies were identified. Health-economic parameters were estimated from registry data, such as utilities and transition probabilities. A cost-effectiveness analysis was constructed for a hypothetical intervention despite evidence shortcomings, for example, aggregated cost data. An R Shiny app with a user-friendly interface was developed for stakeholders to change inputs and evaluate results. Discussion Literature searches for disease analogues proved useful for early modelling in multiple system atrophy, for example, to inform model structures, but surrogate data could only be used when sufficient granularity was available (e.g., micro costing). These findings suggest that early conceptual modelling can help identify data gaps and guide future evidence generation, such as selecting appropriate endpoints for natural history of disease studies. Cost-effectiveness results can be highly uncertain for rare diseases at these early stages and should be considered as part of an iterative modelling framework.


  • Open Access

    Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III

    by Dylan Trundell, Evan W. Davies, Louise Barrett, Stefano Zanigni, Nima Shariati, Rebecca Rogers, Annabelle Monnet, Emma Moore, Nathalie Pross, Gennaro Pagano, et al.

    Background: To understand changes in the underlying progression of early Parkinson's disease, it is important to derive estimates of the threshold for meaningful motor progression on the MDS-UPDRS Part III in OFF medication state. Objective: To estimate this threshold using two approaches: anchor-based analyses, and clinical consensus via a modified Delphi panel. Methods: For the anchor-based analyses, data from a Phase II clinical trial were used. Mean and median MDS-UPDRS Part III change scores were calculated for those participants rated as ‘Minimally worse’ on the Clinical Global Impression of Improvement (using the first visit rated as ‘Minimally worse’ or worse, and at Weeks 24 and 52). Cumulative data up to Week 104 were used to assess the difference between motor progressors’ and non-progressors’ change scores on motor-related outcomes. For the modified Delphi panel, a panel of 13 expert clinicians received an online survey in two rounds and provided responses anonymously. Results: For the anchor-based analyses, estimates of meaningful change ranged from 4−6 points. Numerically worse change scores were identified on motor-related outcomes for participants who had experienced motor progression compared with those who had not. For the modified Delphi panel, consensus was reached in Round 2, with 92% agreeing that 5 points is suitable to define a clinically meaningful motor progression threshold. Conclusions: Results of the anchor-based analyses and modified Delphi panel were consistent, supporting a meaningful motor progression threshold of a worsening of 5 points on the MDS-UPDRS Part III (OFF medication state) in an early Parkinson's disease population.


  • Open Access

    Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update

    by Giovanni Rizzo, Stefano Zanigni, Roberto De Blasi, Daniela Grasso, Davide Martino, Rodolfo Savica, Giancarlo Logroscino

    Brain magnetic resonance (MR) represents a useful and feasible tool for the differential diagnosis of Parkinson’s disease. Conventional MR may reveal secondary forms of parkinsonism and may show peculiar brain alterations of atypical parkinsonian syndromes. Furthermore, advanced MR techniques, such as morphometric-volumetric analyses, diffusion-weighted imaging, diffusion tensor imaging, tractography, proton MR spectroscopy, and iron-content sensitive imaging, have been used to obtain quantitative parameters useful to increase the diagnostic accuracy. Currently, many MR studies have provided both qualitative and quantitative findings, reflecting the underlying neuropathological pattern of the different degenerative parkinsonian syndromes. Although the variability in the methods and results across the studies limits the conclusion about which technique is the best, specific radiologic phenotypes may be identified. Qualitative/quantitative MR changes in the substantia nigra do not discriminate between different parkinsonisms. In the absence of extranigral abnormalities, the diagnosis of PD is more probable, whereas basal ganglia changes (mainly in the putamen) suggest the diagnosis of an atypical parkinsonian syndrome. In this context, changes in pons, middle cerebellar peduncles, and cerebellum suggest the diagnosis of MSA, in midbrain and superior cerebellar peduncles the diagnosis of PSP, and in whole cerebral hemispheres (mainly in frontoparietal cortex with asymmetric distribution) the diagnosis of Corticobasal Syndrome.


  • Brain magnetic resonance metabolic and microstructural changes in adult-onset autosomal dominant leukodystrophy

    by Stefano Zanigni, Rossana Terlizzi, Caterina Tonon, Claudia Testa, David Neil Manners, Sabina Capellari, Roberto Gallassi, Roberto Poda, Laura Ludovica Gramegna, Giovanna Calandra-Buonaura, et al.


  • The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes

    by Stefano Zanigni, Claudia Testa, Giovanna Calandra-Buonaura, Luisa Sambati, Maria Guarino, Anna Gabellini, Stefania Evangelisti, Pietro Cortelli, Raffaele Lodi, Caterina Tonon


  • Binary and Multi-class Parkinsonian Disorders Classification Using Support Vector Machines

    by Rita Morisi, Giorgio Gnecco, Nico Lanconelli, Stefano Zanigni, David Neil Manners, Claudia Testa, Stefania Evangelisti, Laura Ludovica Gramegna, Claudio Bianchini, Pietro Cortelli, et al.


  • Overexpression of blood microRNAs 103a, 30b, and 29a in l -dopa–treated patients with PD

    by Alice Serafin, Luisa Foco, Stefano Zanigni, Hagen Blankenburg, Anne Picard, Alessandra Zanon, Giulia Giannini, Irene Pichler, Maurizio F. Facheris, Pietro Cortelli, et al.

    Objective: The aims of the present study were to profile the expression of several candidate microRNAs (miRNAs) in blood from l-dopa-treated and drug-naive patients with Parkinson disease (PD) vs unaffected controls and to interpret the miRNA expression data in a biological context. Methods: We analyzed RNAs from peripheral blood of 36 l-dopa–treated, 10 drug-naive patients with PD and unaffected controls matched 1:1 by sex and age. We evaluated expression by reverse transcription–quantitative real-time PCR, and we analyzed data using a 2-tailed paired t test. To detect miRNA targets, several miRNA resources were combined to generate an overall score for each candidate gene using weighted rank aggregation. Results: Significant overexpression of miR-103a-3p (p < 0.0001), miR-30b-5p (p = 0.002), and miR-29a-3p (p = 0.005) in treated patients with PD was observed, and promising candidate target genes for these were revealed by an integrated in silico analysis. Conclusions: We revealed 3 candidate biomarkers for PD. miRNAs 30b-5p and 29a-3p replicated a documented deregulation in PD albeit opposite to published data, while for miR-103a-3p, we demonstrated for the first time an overexpression in treated patients with PD. Expression studies in patients and/or in isolated peripheral blood mononuclear cells before and after l-dopa administration are necessary to define the involvement of l-dopa treatment in the observed overexpression. Our in silico analysis to prioritize targets of deregulated miRNAs identified candidate target genes, including genes related to neurodegeneration and PD. Despite the preliminary character of our study, the results provide a rationale for further clarifying the role of the identified miRNAs in the pathogenesis of PD and for validating their diagnostic potential.


  • Open Access

    Identification of a set of endogenous reference genes for miRNA expression studies in Parkinson’s disease blood samples

    by Alice Serafin, Luisa Foco, Hagen Blankenburg, Anne Picard, Stefano Zanigni, Alessandra Zanon, Peter P Pramstaller, Andrew A Hicks, Christine Schwienbacher

    Research on microRNAs (miRNAs) is becoming an increasingly attractive field, as these small RNA molecules are involved in several physiological functions and diseases. To date, only few studies have assessed the expression of blood miRNAs related to Parkinson’s disease (PD) using microarray and quantitative real-time PCR (qRT-PCR). Measuring miRNA expression involves normalization of qRT-PCR data using endogenous reference genes for calibration, but their choice remains a delicate problem with serious impact on the resulting expression levels. The aim of the present study was to evaluate the suitability of a set of commonly used small RNAs as normalizers and to identify which of these miRNAs might be considered reliable reference genes in qRT-PCR expression analyses on PD blood samples. Commonly used reference genes snoRNA RNU24, snRNA RNU6B, snoRNA Z30 and miR-103a-3p were selected from the literature. We then analyzed the effect of using these genes as reference, alone or in any possible combination, on the measured expression levels of the target genes miR-30b-5p and miR-29a-3p, which have been previously reported to be deregulated in PD blood samples. We identified RNU24 and Z30 as a reliable and stable pair of reference genes in PD blood samples.


  • Association between restless legs syndrome and migraine: a population‐based study

    by Stefano Zanigni, Giulia Giannini, Roberto Melotti, Cristian Pattaro, Federica Provini, Sabina Cevoli, Maurizio F. Facheris, Pietro Cortelli, Peter P. Pramstaller

    Background and purpose: A higher prevalence of restless legs syndrome (RLS) in migraineurs has been reported in clinical samples and in two large‐scale clinical trials performed on healthcare workers but general population‐based studies on this topic are lacking. The aim of this study was to assess the association between migraine and RLS in an Italian rural adult population‐based setting.Methods: The presence of migraine and RLS was assessed via a computer‐assisted personal interview and self‐administered questionnaires according to current diagnostic criteria in 1567 participants of a preliminary phase of an adult population‐based study performed in South Tyrol, Italy.Results: Migraineurs had an increased risk of having RLS also after adjustment for confounding factors such as age, sex, major depression, anxiety and sleep quality (odds ratio 1.79; confidence interval 1.00–3.19; P = 0.049). This association was not modified by aura status and possible causes of secondary RLS. RLS was not significantly associated with tension‐type headache.Conclusions: Restless legs syndrome and migraine were associated in our rural adult population. This association could be explained by a possible shared pathogenic pathway which would implicate new management strategies of these two disorders.